[1] C. Liedtke et al., “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer,” J Clin Oncol, vol. 26, no. 8, pp. 1275–1281, 2008.
[2] R. Dent et al., “Triple-negative breast cancer: clinical features and patterns of recurrence,” Clin Cancer Res, vol. 13, no. 15 Pt 1, pp. 4429–4434, 2007.
[3] S. M. Reddy et al., “Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity,” Br. J. Cancer, 2018.
[4] K. E. McCann and S. A. Hurvitz, “Advances in the use of PARP inhibitor therapy for breast cancer,” Drugs in Context. 2018.
[5] A. Ashworth, C. J. Lord, and J. S. Reis-Filho, “Gentic interactions in cancer progression and treatment,” Cell, vol. 145, no. 1, pp. 30–38, 2011.
[6] P. Schmid et al., “Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial,” Lancet Oncol., 2020.
[7] B. D. Lehmann et al., “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies,” J. Clin. Invest., 2011.
[8] S. Banerjee et al., “Basal-like breast carcinomas: Clinical outcome and response to chemotherapy,” J. Clin. Pathol., 2006.
[9] F. Ma et al., “Enriched CD44+/CD24- population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC),” Cancer Lett., 2014.
[10] V. Adorno-Cruz et al., “Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance,” Cancer Res, vol. 75, no. 6, pp. 924–929, 2015.
[11] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proc Natl Acad Sci U S A, vol. 100, no. 7, pp. 3983–3988, 2003.
[12] C. Hirschmann-Jax et al., “A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells,” Proc Natl Acad Sci U S A, vol. 101, no. 39, pp. 14228–14233, 2004.
[13] V. V Ogryzko, R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani, “The transcriptional coactivators p300 and CBP are histone acetyltransferases,” Cell, vol. 87, no. 5, pp. 953–959, 1996.
[14] R. H. Goodman and S. Smolik, “CBP/p300 in cell growth, transformation, and development,” Genes Dev, vol. 14, no. 13, pp. 1553–1577, 2000.
[15] N. G. Iyer, H. Ozdag, and C. Caldas, “p300/CBP and cancer,” Oncogene, vol. 23, no. 24, pp. 4225–4231, 2004.
[16] S. A. Gayther et al., “Mutations truncating the EP300 acetylase in human cancers,” Nat Genet, vol. 24, no. 3, pp. 300–303, 2000.
[17] M. Asaduzzaman et al., “Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer,” Breast Cancer Res Treat, vol. 163, no. 3, pp. 461–474, 2017.
[18] Z. Mahmud et al., “Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases,” Biochem. Pharmacol., 2019.
[19] M. E. Fermento et al., “Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization,” Exp. Mol. Pathol., 2014.
[20] M. H. Cho et al., “DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression,” Nat. Commun., 2015.
[21] V. Bemanian et al., “Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer,” Breast Cancer Res. Treat., 2018.
[22] C. Kilkenny, W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, “Improving bioscience research reporting: The arrive guidelines for reporting animal research,” PLoS Biol., 2010.
[23] G. Ciriello et al., “Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer,” Cell, vol. 163, no. 2, pp. 506–519, 2015.
[24] N. Cancer Genome Atlas, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012.
[25] E. Cerami et al., “The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data,” Cancer Discov, vol. 2, no. 5, pp. 401–404, 2012.
[26] B. Györffy et al., “An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients,” Breast Cancer Research and Treatment. 2010.
[27] L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool, and D. G. Tang, “Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 + and ABCG2 - cancer cells are similarly tumorigenic,” Cancer Res., 2005.
[28] S. Zhou, J. J. Morris, Y. Barnes, L. Lan, J. D. Schuetz, and B. P. Sorrentino, “Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo,” Proc. Natl. Acad. Sci. U. S. A., 2002.
[29] O. Leis et al., “Sox2 expression in breast tumours and activation in breast cancer stem cells,” Oncogene, 2012.
[30] C. Ginestier et al., “ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome,” Cell Stem Cell, 2007.
[31] Y. Liu et al., “Lack of correlation of stem cell markers in breast cancer stem cells.,” Br. J. Cancer, 2014.
[32] K. M. Bussard, L. Mutkus, K. Stumpf, C. Gomez-Manzano, and F. C. Marini, “Tumor-associated stromal cells as key contributors to the tumor microenvironment,” Breast Cancer Research. 2016.
[33] P. Maris et al., “Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer,” PLoS Med., 2015.
[34] R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nature Reviews Cancer. 2006.
[35] C. Dou et al., “P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts,” Gastroenterology, 2018.
[36] A. Prat et al., “Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer,” Breast Cancer Res., 2010.
[37] D. Xiong, Y. Wang, A. K. Singavi, A. C. Mackinnon, B. George, and M. You, “Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer,” iScience, 2018.
[38] Y. Zou et al., “The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells,” J. Biol. Chem., 2018.
[39] X. Hou et al., “p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells,” BMC Cancer, vol. 18, no. 1, Jun. 2018.
[40] Z. W. Liao et al., “P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line,” Oncol. Lett., 2017.
[41] L. M. Lasko et al., “Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours,” Nature, vol. 550, no. 7674, pp. 128–132, Oct. 2017.
[42] L. Seguin, J. S. Desgrosellier, S. M. Weis, and D. A. Cheresh, “Integrins and cancer: Regulators of cancer stemness, metastasis, and drug resistance,” Trends in Cell Biology. 2015.
[43] S. G. Pohl, N. Brook, M. Agostino, F. Arfuso, A. P. Kumar, and A. Dharmarajan, “Wnt signaling in triple-negative breast cancer,” Oncogenesis. 2017.
[44] B. Frugtniet and T. A. Martin, “Role of the wasp and wave family proteins in breast cancer invasion and metastasis,” Breast Cancer Targets Ther., 2015.
[45] N. E. Bhola et al., “Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population,” Cancer Res., 2016.
[46] H. Kim, Q. Lin, and Z. Yun, “BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors,” Sci. Rep., 2019.
[47] A. Baker et al., “Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival,” Oncogene, 2018.
[48] P. Shi et al., “Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation,” Cell Discov., 2017.
[49] G. V. Vijay et al., “GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer,” Breast Cancer Res., 2019.
[50] S. Légaré, C. Chabot, and M. Basik, “SPEN, a new player in primary cilia formation and cell migration in breast cancer,” Breast Cancer Res., 2017.
[51] A. Ring et al., “CBP/Β-catenin/FOXM1 is a novel therapeutic target in triple negative breast cancer,” Cancers (Basel)., 2018.
[52] H. X. Yan et al., “DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats,” Oncogene, 2013.
[53] R. U. Jänicke, D. Sohn, and K. Schulze-Osthoff, “The dark side of a tumor suppressor: Anti-apoptotic p53,” Cell Death and Differentiation. 2008.